Characterization of specific p63 and p63-N-terminal isoform antibodies and their application for immunohistochemistry

Virchows Archiv

Volumn 463, Issue 3, 2013, Pages 415-425

  Nekulova, Marta ^a   Holcakova, Jitka ^a   Nenutil, Rudolf ^a   Stratmann, Rembert ^b   Bouchalova, Pavla ^a   Müller, Petr ^a   Mouková, Lucie ^a   Coates, Philip J ^c   Vojtesek, Borivoj ^a  

^a MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^b DCS Innovative Diagnostik Systeme   (Germany)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Cervical cancer; Development; p63; TAp63

Indexed keywords

MONOCLONAL ANTIBODY; PROTEIN; PROTEIN P53; PROTEIN P63; PROTEIN P73; TAP63 PROTEIN; UNCLASSIFIED DRUG;

ADENOID CYSTIC CARCINOMA; ADENOSQUAMOUS CARCINOMA; AMINO TERMINAL SEQUENCE; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ANTIGEN RETRIEVAL; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CROSS REACTION; DNA BINDING; EMBRYO; EPITOPE MAPPING; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; LARGE CELL NEUROENDOCRINE CARCINOMA; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RABBIT; RAT; SQUAMOUS CELL CARCINOMA; TUMOR INVASION; UTERINE CERVIX CARCINOMA; WESTERN BLOTTING;

ADENOCARCINOMA; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELLS, CULTURED; CROSS REACTIONS; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MEMBRANE PROTEINS; MICE; NUCLEAR PROTEINS; PROTEIN ISOFORMS; RATS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; UTERINE CERVICAL NEOPLASMS;

EID: 84884147665     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-013-1459-4     Document Type: Article

References (49)

1. Belyi VA, Ak P, Markert E et al (2010) The origins and evolution of the p53 family of genes. Cold Spring Harb Perspect Biol 2:a001198
2. Candi E, Dinsdale D, Rufini A et al (2007) TAp63 and DeltaNp63 in cancer and epidermal development. Cell Cycle 6:274-285
3. Crum CP, McKeon FD (2010) p63 in epithelial survival, germ cell surveillance, and neoplasia. Annu Rev Pathol 5:349-371
4. Nekulova M, Holcakova J, Coates P, Vojtesek B (2011) The role of p63 in cancer, stem cells and cancer stem cells. Cell Mol Biol Lett 16:296-327
5. Hibi K, Trink B, Patturajan M et al (2000) AIS is an oncogene amplified in squamous cell carcinoma. Proc Natl Acad Sci U S A 97:5462-5467
6. Massion PP, Taflan PM, Jamshedur Rahman SM et al (2003) Significance of p63 amplification and overexpression in lung cancer development and prognosis. Cancer Res 63:7113-7121
7. Thurfjell N, Coates PJ, Uusitalo T et al (2004) Complex p63 mRNA isoform expression patterns in squamous cell carcinoma of the head and neck. Int J Oncol 25:27-35
8. Koster MI, Kim S, Mills AA, DeMayo FJ, Roop DR (2004) p63 is the molecular switch for initiation of an epithelial stratification program. Genes Dev 18:126-131
9. Koster MI, Lu SL, White LD, Wang XJ, Roop DR (2006) Reactivation of developmentally expressed p63 isoforms predisposes to tumor development and progression. Cancer Res 66:3981-3986
10. Gressner O, Schilling T, Lorenz K et al (2005) TAp63alpha induces apoptosis by activating signaling via death receptors and mitochondria. EMBO J 24:2458-2471
11. Suh EK, Yang A, Kettenbach A et al (2006) p63 protects the female germ line during meiotic arrest. Nature 444:624-628
12. Gonfloni S, Di Tella L, Caldarola S et al (2009) Inhibition of the c-Abl-TAp63 pathway protects mouse oocytes from chemotherapy-induced death. Nat Med 15:1179-1185
13. Guo X, Keyes WM, Papazoglu C et al (2009) TAp63 induces senescence and suppresses tumorigenesis in vivo. Nat Cell Biol 11:1451-1457
14. Mukhopadhyay S, Katzenstein AL (2011) Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: Utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6. Am J Surg Pathol 35:15-25
15. Rekhtman N, Ang DC, Sima CS, Travis WD, Moreira AL (2011) Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. Mod Pathol 24:1348-1359
16. Sterlacci W, Savic S, Schmid T et al (2012) Tissue-sparing application of the newly proposed IASLC/ATS/ERS classification of adenocarcinoma of the lung shows practical diagnostic and prognostic impact. Am J Clin Pathol 137:946-956
17. Carvalho JC, Thomas DG, McHugh JB, Shah RB, Kunju LP (2012) p63, CK7, PAX8 and INI-1: an optimal immunohistochemical panel to distinguish poorly differentiated urothelial cell carcinoma from high-grade tumours of the renal collecting system. Histopathology 60:597-608
18. Molinie V, Herve JM, Lugagne PM, Baglin AC (2004) P63 and p504s cocktail is useful in ambiguous lesions of the prostate. Histopathology 44:403-404
19. Humphrey PA (2007) Diagnosis of adenocarcinoma in prostate needle biopsy tissue. J Clin Pathol 60:35-42
20. Matos I, Dufloth R, Alvarenga M, Zeferino LC, Schmitt F (2005) p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch 447:688-694
21. Reis-Filho JS, Milanezi F, Steele D et al (2006) Metaplastic breast carcinomas are basal-like tumours. Histopathology 49:10-21
22. Urist MJ, Di Como CJ, Lu ML et al (2002) Loss of p63 expression is associated with tumor progression in bladder cancer. Am J Pathol 161:1199-1206
23. Koga F, Kawakami S, Fujii Y et al (2003) Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder. Clin Cancer Res 9:5501-5507
24. Fukushima H, Koga F, Kawakami S et al (2009) Loss of DeltaNp63alpha promotes invasion of urothelial carcinomas via N-cadherin/Src homology and collagen/extracellular signal-regulated kinase pathway. Cancer Res 69:9263-9270
25. Choi W, Shah JB, Tran M et al (2012) p63 expression defines a lethal subset of muscle-invasive bladder cancers. PLoS One 7:e30206
26. Karni-Schmidt O, Castillo-Martin M, Shen TH et al (2011) Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression. Am J Pathol 178:1350-1360
27. Lo Muzio L, Santarelli A, Caltabiano R et al (2005) p63 overexpression associates with poor prognosis in head and neck squamous cell carcinoma. Hum Pathol 36:187-194
28. Moergel M, Abt E, Stockinger M, Kunkel M (2010) Overexpression of p63 is associated with radiation resistance and prognosis in oral squamous cell carcinoma. Oral Oncol 46:667-671
29. Lo Muzio L, Santarelli A, Caltabiano R et al (2006) p63 expression correlates with pathological features and biological behaviour of odontogenic tumours. Histopathology 49:211-214
30. Borba M, Cernea C, Dias F et al (2010) Expression profile of p63 in 127 patients with laryngeal squamous cell carcinoma. ORL J Otorhinolaryngol Relat Spec 72:319-324
31. Kim YJ, Go H, Wu HG, Jeon YK, Park SW, Lee SH (2011) Immunohistochemical study identifying prognostic biomolecular markers in nasopharyngeal carcinoma treated by radiotherapy. Head Neck 33:1458-1466
32. Cho NH, Kim YB, Park TK, Kim GE, Park K, Song KJ (2003) P63 and EGFR as prognostic predictors in stage IIB radiation-treated cervical squamous cell carcinoma. Gynecol Oncol 91:346-353
33. Hiroshima K, Iyoda A, Shida T et al (2006) Distinction of pulmonary large cell neuroendocrine carcinoma from small cell lung carcinoma: a morphological, immunohistochemical, and molecular analysis. Mod Pathol 19:1358-1368
34. Asioli S, Righi A, de Biase D et al (2011) Expression of p63 is the sole independent marker of aggressiveness in localised (stage I-II) Merkel cell carcinomas. Mod Pathol 24:1451-1461
35. Lo Muzio L, Campisi G, Farina A et al (2007) Effect of p63 expression on survival in oral squamous cell carcinoma. Cancer Invest 25:464-469
36. Hanker L, Karn T, Ruckhaeberle E et al (2010) Clinical relevance of the putative stem cell marker p63 in breast cancer. Breast Cancer Res Treat 122:765-775
37. Leong CO, Vidnovic N, DeYoung MP, Sgroi D, Ellisen LW (2007) The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. J Clin Invest 117:1370-1380
38. Zangen R, Ratovitski E, Sidransky D (2005) DeltaNp63alpha levels correlate with clinical tumor response to cisplatin. Cell Cycle 4:1313-1315
39. Bishop JA, Teruya-Feldstein J, Westra WH, Pelosi G, Travis WD, Rekhtman N (2012) p40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Mod Pathol 25:405-415
40. Rosenbluth JM, Johnson K, Tang L, Triplett T, Pietenpol JA (2009) Evaluation of p63 and p73 antibodies for cross-reactivity. Cell Cycle 8:3702-3706
41. Ying H, Chang DL, Zheng H, McKeon F, Xiao ZX (2005) DNA-binding and transactivation activities are essential for TAp63 protein degradation. Mol Cell Biol 25:6154-6164
42. Petitjean A, Ruptier C, Tribollet V et al (2008) Properties of the six isoforms of p63: p53-like regulation in response to genotoxic stress and cross talk with DeltaNp73. Carcinogenesis 29:273-281
43. Nylander K, Vojtesek B, Nenutil R et al (2002) Differential expression of p63 isoforms in normal tissues and neoplastic cells. J Pathol 198:417-427
44. Chilosi M, Zamò A, Brighenti A et al (2003) Constitutive expression of DeltaN-p63alpha isoform in human thymus and thymic epithelial tumours. Virchows Arch 443:175-183
45. Burstein DE, Nagi C, Wang BY, Unger P (2004) Immunohistochemical detection of p53 homolog p63 in solid cell nests, papillary thyroid carcinoma, and Hashimoto's thyroiditis: a stem cell hypothesis of papillary carcinoma oncogenesis. Hum Pathol 35:465-473
46. Pruneri G, Fabris S, Dell'Orto P et al (2005) The transactivating isoforms of p63 are overexpressed in high-grade follicular lymphomas independent of the occurrence of p63 gene amplification. J Pathol 206:337-345
47. Jo VY, Fletcher CDM (2011) P63 immunohistochemical staining is limited in soft tissue tumors. Am J Clin Pathol 136:762-766
48. Sun R, Zhang Y, Lv Q et al (2011) Toll-like receptor 3 (TLR3) induces apoptosis via death receptors and mitochondria by up-regulating the transactivating p63 isoform α (TAP63α). J Biol Chem 286:15918-15928
49. Su X, Chakravarti D, Cho MS et al (2010) TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs. Nature 467:986-990